BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Grabenstein JD, Weber DJ. Pneumococcal serotype diversity among adults in various countries, influenced by pediatric pneumococcal vaccination uptake. Clin Infect Dis 2014;58:854-64. [PMID: 24344141 DOI: 10.1093/cid/cit800] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
Number Citing Articles
1 Skoczyńska A, Kuch A, Sadowy E, Waśko I, Markowska M, Ronkiewicz P, Matynia B, Bojarska A, Wasiak K, Gołębiewska A, van der Linden M, Hryniewicz W; Participants of a laboratory-based surveillance of community acquired invasive bacterial infections (BINet). Recent trends in epidemiology of invasive pneumococcal disease in Poland. Eur J Clin Microbiol Infect Dis 2015;34:779-87. [DOI: 10.1007/s10096-014-2283-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
2 Grabenstein JD, Musey LK. Differences in serious clinical outcomes of infection caused by specific pneumococcal serotypes among adults. Vaccine 2014;32:2399-405. [PMID: 24637174 DOI: 10.1016/j.vaccine.2014.02.096] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 6.9] [Reference Citation Analysis]
3 Imöhl M, Reinert RR, van der Linden M. Antibiotic susceptibility rates of invasive pneumococci before and after the introduction of pneumococcal conjugate vaccination in Germany. International Journal of Medical Microbiology 2015;305:776-83. [DOI: 10.1016/j.ijmm.2015.08.031] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
4 Vila-corcoles A, Hospital I, Ochoa-gondar O, Satue E, de Diego C, Vila-rovira A, Gómez-bertomeu F, Raga X, Aragón M. Clinical effectiveness of 13-valent and 23-valent pneumococcal vaccination in middle-aged and older adults: The EPIVAC cohort study, 2015–2016. Vaccine 2020;38:1170-80. [DOI: 10.1016/j.vaccine.2019.11.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Caierão J, Sant'Anna FH, Hawkins P, Cunha GR, Mott M, Falci DR, d'Azevedo PA, McGee L, Dias C. Characteristics of serogroup 20 S.pneumoniae isolates from Brazil. BMC Infect Dis 2016;16:418. [PMID: 27527077 DOI: 10.1186/s12879-016-1773-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Camou F, Issa N, Bessede É, Mourissoux G, Guisset O. Usefulness of pneumococcal antigen urinary testing in the intensive care unit? Med Mal Infect 2015;45:318-23. [PMID: 26344817 DOI: 10.1016/j.medmal.2015.08.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
7 Grabenstein JD, Musher DM. Pneumococcal Polysaccharide Vaccines. Plotkin's Vaccines. Elsevier; 2018. pp. 816-840.e13. [DOI: 10.1016/b978-0-323-35761-6.00046-8] [Cited by in Crossref: 5] [Article Influence: 1.3] [Reference Citation Analysis]
8 Choi MJ, Song JY, Cheong HJ, Jeon JH, Kang SH, Jung EJ, Noh JY, Kim WJ. Clinical usefulness of pneumococcal urinary antigen test, stratified by disease severity and serotypes. J Infect Chemother 2015;21:672-9. [PMID: 26212866 DOI: 10.1016/j.jiac.2015.06.003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
9 Morimoto K, Suzuki M, Ishifuji T, Yaegashi M, Asoh N, Hamashige N, Abe M, Aoshima M, Ariyoshi K; Adult Pneumonia Study Group-Japan (APSG-J). The burden and etiology of community-onset pneumonia in the aging Japanese population: a multicenter prospective study. PLoS One 2015;10:e0122247. [PMID: 25822890 DOI: 10.1371/journal.pone.0122247] [Cited by in Crossref: 88] [Cited by in F6Publishing: 85] [Article Influence: 12.6] [Reference Citation Analysis]
10 Khan MN, Coleman JR, Vernatter J, Varshney AK, Dufaud C, Pirofski LA. An ahemolytic pneumolysin of Streptococcus pneumoniae manipulates human innate and CD4⁺ T-cell responses and reduces resistance to colonization in mice in a serotype-independent manner. J Infect Dis 2014;210:1658-69. [PMID: 25001458 DOI: 10.1093/infdis/jiu321] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
11 Jiang Y, Gauthier A, Keeping S, Carroll S. Cost-effectiveness of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK. Expert Rev Pharmacoecon Outcomes Res 2014;14:913-27. [PMID: 25189087 DOI: 10.1586/14737167.2014.950232] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
12 Ubukata K, Chiba N, Hanada S, Morozumi M, Wajima T, Shouji M, Iwata S; Invasive Pneumococcal Diseases Surveillance Study Group. Serotype Changes and Drug Resistance in Invasive Pneumococcal Diseases in Adults after Vaccinations in Children, Japan, 2010-2013. Emerg Infect Dis 2015;21:1956-65. [PMID: 26485679 DOI: 10.3201/eid2111.142029] [Cited by in Crossref: 46] [Cited by in F6Publishing: 39] [Article Influence: 7.7] [Reference Citation Analysis]
13 Hunter P, Fryhofer SA, Szilagyi PG. Vaccination of Adults in General Medical Practice. Mayo Clin Proc 2020;95:169-83. [PMID: 31902413 DOI: 10.1016/j.mayocp.2019.02.024] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
14 Zou JT, Jing HM, Yuan Y, Lei LH, Chen ZF, Gou Q, Xiong QS, Zhang XL, Zhao Z, Zhang XK, Zeng H, Zou QM, Zhang JY. Pore-forming alpha-hemolysin efficiently improves the immunogenicity and protective efficacy of protein antigens. PLoS Pathog 2021;17:e1009752. [PMID: 34288976 DOI: 10.1371/journal.ppat.1009752] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Müller A, Salmen A, Aebi S, de Gouveia L, von Gottberg A, Hathaway LJ. Pneumococcal serotype determines growth and capsule size in human cerebrospinal fluid. BMC Microbiol 2020;20:16. [PMID: 31959125 DOI: 10.1186/s12866-020-1700-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Jiang Y, Gauthier A, Keeping S, Carroll S. A public health and budget impact analysis of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK. Expert Rev Pharmacoecon Outcomes Res 2014;14:901-11. [PMID: 25186657 DOI: 10.1586/14737167.2014.953932] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
17 Wang MC, Wang YP, Chu CH, Tu TY, Shiao AS, Chou P. Impact of pneumococcal conjugate vaccine on pediatric tympanostomy tube insertion in partial immunized population. ScientificWorldJournal 2015;2015:248678. [PMID: 25839052 DOI: 10.1155/2015/248678] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
18 Ciprero KL, Marchese RD, Richard P, Baudin M, Sterling TM, Manoff SB, Radley D, Stek JE, Soubeyrand B, Grabenstein JD, Samson SI, Musey LK. Vaccination of adults with 23-valent pneumococcal polysaccharide vaccine induces robust antibody responses against pneumococcal serotypes associated with serious clinical outcomes. Hum Vaccin Immunother 2016;12:2135-41. [PMID: 27002793 DOI: 10.1080/21645515.2016.1156270] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
19 Vila-Corcoles A, Ochoa-Gondar O, Hospital I, de Diego C, Satué E, Bladé J, Ansa X, Guzmán JA, Salsench E, Ramos F. Pneumococcal vaccination coverages among low-, intermediate-, and high-risk adults in Catalonia. Hum Vaccin Immunother 2016;12:2953-8. [PMID: 27454779 DOI: 10.1080/21645515.2016.1210744] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
20 Vila-Córcoles Á, Salsench-Serrano E, Ochoa-Gondar O, Aguirre-Chavarría C, Utrera-Aponte J, Guzmán-Ávalos J. [Incidence and lethality of invasive pneumococcal disease in Tarragona, Spain, 2006-2009]. Enferm Infecc Microbiol Clin 2015;33:186-9. [PMID: 25613558 DOI: 10.1016/j.eimc.2014.09.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
21 Vila-Córcoles A, Ochoa-Gondar O. [Pneumococcal disease in adults: Risk levels and vaccine recommendations]. Aten Primaria 2017;49:111-7. [PMID: 27765456 DOI: 10.1016/j.aprim.2016.06.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
22 Yang H, Linden SB, Wang J, Yu J, Nelson DC, Wei H. A chimeolysin with extended-spectrum streptococcal host range found by an induced lysis-based rapid screening method. Sci Rep 2015;5:17257. [PMID: 26607832 DOI: 10.1038/srep17257] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 5.3] [Reference Citation Analysis]
23 Wattal C, Goel N, Byotra SP. Prevalence of pneumococcal serotypes in adults ≥50 years of age. Indian J Med Microbiol 2017;35:95-100. [PMID: 28303826 DOI: 10.4103/ijmm.IJMM_16_132] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]